Skip to content

Clinical study on breast cancer circulating tumor cells detected by blood component separation

Clinical study on breast cancer circulating tumor cells detected by blood component separation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDT-12002375
Enrollment
Unknown
Registered
2012-07-22
Start date
2012-07-09
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Gold Standard:
Index test:

Sponsors

Breast Disease Center, the First Affiliated Hospital of Third Military University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. The patients primarily diagnosed as having breast cancer have not received any treatment yet; 2. Signed informed consent; 3. 18 to 60 years; 4. Capacity to comply with program; 5. No history of other malignant tumors; 6. Acceptable general condition, ECOG score: 0 to 1; 7. The requirements of blood, liver and kidney function (1) Blood function: 1) absolute neutrophil cell count >=1.5*10^9/L; 2) platelet count >=100*10^9/L; 3) HGB >=100g/L, HCT >=0.30; (2) Liver function: total bilirubin =50 mL/min and urinary protein <2+; (4) Coagulation: within 7 days before enrollment, the international normalized ratio (INR) <=1.5 and partial prothrombin time (PPT or aPTT) <=1.5 ULN.

Exclusion criteria

Exclusion criteria: 1. The female patients in pregnancy or lactation; 2. History of lumpectomy; 3. With clear surgical contraindications; 4. With other diseases, which have not been fully controlled, (the blood sampling may trigger the disease attack; 5. History of blood donation reaction or tardive lipothymia; 6. Associated with coronary heart disease, congestive heart failure, severe aortic stenosis, ventricular arrhythmia, severe hypertension and other cardio-cerebral vascular diseases. The critically ill patients; 7. HGB <100g/L or with bacterial infections; 8. Taking the drugs which inhibit compensatory cardiovascular responses; 9. The other factors unsuitable for the enrollment.

Design outcomes

Primary

MeasureTime frame
overall survival;disease free survival;

Countries

China

Contacts

Public ContactJiang Jun
renlin@medmail.com.cn+86 023-68765633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026